Objective:
To evaluate the safety and efficacy of Tiespectus (MK-8748) for treating macular edema secondary to branch retinal vein occlusion (BRVO).
Key Findings:
- Mean gain of 16.7 letters in BCVA at 12 weeks.
- Mean reduction of 157.8 µm in CST at 12 weeks.
- No serious ocular or systemic adverse events reported.
- No dose-limiting toxicity observed.
Interpretation:
Tiespectus shows promising results in improving visual function and retinal anatomy in patients with BRVO, supporting further clinical development.
Limitations:
- Small sample size of 12 patients.
- Short follow-up period of 12 weeks.
Conclusion:
The positive outcomes from the RIOJA trial suggest that Tiespectus may be a viable treatment option for BRVO, with plans for late-stage clinical trials in the near future.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.